Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Minocycline for Microglial Activation in ASD
NCT03117530Phase 1Suspended
- Sponsor
- University of California, Los Angeles
- Start
- Apr 2017
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of minocycline in Autism Spectrum Disorder (ASD) (2 arms), sponsored by University of California, Los Angeles. Primary endpoint: CNS microglial activation via [11C]-DAA1106 binding at Week 12. Started Apr 2017; status: suspended.
02
Drugs
minocycline
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT03117530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03117530.